Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RIGL, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Olutasidenib FDA approved Dec 2022 · Rezlidhia |
AML (Acute Myeloid Leukemia) | Phase 4 · NCT07486713 | Recruiting |
| Pralsetinib FDA approved Sep 2020 · Gavreto |
NSCLC (Non-small Cell Lung Cancer) | Phase 4 · NCT07704658 | Recruiting |
| Fostamatinib FDA approved Apr 2018 · Tavalisse |
Covid19 | Phase 3 · NCT04629703 | Completed |
| Vepdegestrant FDA approved May 2026 · Veppanu |
Breast Cancer | Phase 1/2 · NCT06125522 | Terminated |
| Imiquimod | Actinic Keratoses | Phase 4 · NCT00774787 | Completed |
| Cytochrome P450 1A2 | AML (Acute Myeloid Leukemia) | Phase 4 · NCT07486713 | Recruiting |
| Cytochrome P450 3A4 | NSCLC (Non-small Cell Lung Cancer) | Phase 4 · NCT07704658 | Recruiting |
| R926112 | Rhinitis, Allergic, Seasonal | Phase 2 · NCT00115089 | Completed |
| Gilteritinib | Targeted Therapy | Phase 2 · NCT07032727 | Recruiting |
| LY3871801 | Rheumatoid Arthritis | Phase 2 · NCT05848258 | Completed |
| Temozolomide | High Grade Glioma | Phase 2 · NCT06161974 | Recruiting |
| R348 Ophthalmic Solution, 0.2% | Chronic Graft-versus-host Disease | Phase 2 · NCT02040623 | Completed |
| R348 Ophthalmic Solution, 0.5% | Chronic Graft-versus-host Disease | Phase 2 · NCT02040623 | Completed |
| R788 | Rheumatoid Arthritis | Phase 2 · NCT00326339 | Completed |
| Dual IRAK1/4 Inhibitor R906289 Monosodium | Low Risk Myelodysplastic Syndromes | Phase 1/2 · NCT05308264 | Recruiting |
| R932333 | Lupus Erythematosus, Discoid | Phase 2 · NCT01597050 | Completed |
Also used in these trials (approved or third-party drugs, not RIGL's own candidates): Ruxolitinib, Venetoclax, Azacitidine, Cladribine, Cytarabine, Decitabine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RIGL holds $120.7M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RIGL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 2,065,776 | 10.97% | 2026-09-30 |
| Soleus Capital Master Fund, L.P. | Institution (13G, 5%+) | 1,843,504 | 9.79% | 2026-06-30 |
| Soleus Capital Management, L.P. | Institution (13F) | 1,843,504 | 9.79% | 2026-09-30 |
| Armistice Capital, LLC | Institution (13G, 5%+) | 1,672,000 | 8.88% | 2026-06-30 |
| Morgan Stanley | Institution (13G, 5%+) | 1,212,656 | 6.44% | 2026-09-30 |
| American Century Companies Inc | Institution (13F) | 1,043,966 | 5.54% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 879,862 | 4.67% | 2026-09-30 |
| LSV Asset Management | Institution (13F) | 787,408 | 4.18% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 782,703 | 4.16% | 2026-09-30 |
| Assenagon Asset Management S.A. | Institution (13F) | 535,685 | 2.84% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 482,976 | 2.56% | 2026-09-30 |
| Raul R Rodriguez CEO, President, Director · +31,700 options |
Insider | 273,362 | 1.45% | 2026-09-01 |
Share count 18,829,972 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-02 filed 2026-09-03 |
Schorno Dean L |
Option exercise (M) | 2,000 | – | – |
| 2026-09-02 filed 2026-09-03 |
Schorno Dean L |
Option exercise (M) | 620 | – | – |
| 2026-09-02 filed 2026-09-03 |
Schorno Dean L |
Option exercise (M) | 694 | – | – |
| 2026-09-02 filed 2026-09-03 |
Schorno Dean L |
Option exercise (M) | 1,286 | $24.20 | 82,962 |
| 2026-09-02 filed 2026-09-03 |
Schorno Dean L |
Option exercise (M) | 2,000 | $24.20 | 81,676 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RIGL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →